LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Suletud

Sektor Tervishoid

467.89 0.07

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

467.08

Max

470.91

Põhinäitajad
By Trading Economics
Sissetulek	-4.7B -3.6B
Müük	-40M 2.7B
P/E Sektori keskmine	30.09 103.001
Aktsiakasum	-12.83
Kasumimarginaal	-135.608
Töötajad	5,400
EBITDA	263M 1.3B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+9.17 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. nov 2024

Turustatistika
By TradingEconomics
Turukapital	128B
Eelmine avamishind	467.82
Eelmine sulgemishind	467.89

Uudiste sentiment

By Acuity

50%

94 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

463.41 / 481.19 Toetus ja vastupanu

Vertex Pharmaceuticals Inc Graafik

Seotud uudised

1. aug 2024, 20:45 UTC

Tulu

Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

6. mai 2024, 20:37 UTC

Tulu

Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug

10. apr 2024, 22:48 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition

10. apr 2024, 21:40 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.

10. apr 2024, 21:24 UTC

Omandamised, ülevõtmised, äriostud

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update

10. apr 2024, 20:30 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion

1. aug 2024, 20:30 UTC

Tulu

Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

1. aug 2024, 20:03 UTC

Tulu

Vertex Pharmaceuticals: Raised Full Yr Pdt Rev Guidanceto $10.65B - $10.85 B >VRTX

1. aug 2024, 20:02 UTC

Tulu

Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX

1. aug 2024, 20:02 UTC

Tulu

Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX

27. juuni 2024, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Vertex Also Sees About $200M of Transaction-Related Compensation Expense Associated With Acceleration of Unvested Awards Pursuant to Alpine Equity Incentive Plans

27. juuni 2024, 20:14 UTC

Omandamised, ülevõtmised, äriostud

Vertex Pharmaceuticals Expects to Record About $4.4B One-Time Acquired In-Process R&D Expense Related to May Purchase of Alpine Immune Sciences

6. mai 2024, 21:00 UTC

Tulu

Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key -- IBD

6. mai 2024, 20:15 UTC

Tulu

Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook -- IBD

6. mai 2024, 20:03 UTC

Tulu

Vertex Pharmaceuticals: Reiterated Full Yr 2024 Fincl Guidance, Including Pdt Rev Guidance of $10.55B to $10.75 B >VRTX

6. mai 2024, 20:03 UTC

Tulu

Vertex Pharmaceuticals 1Q Rev $2.69B >VRTX

6. mai 2024, 20:01 UTC

Tulu

Vertex Pharmaceuticals 1Q Net $1.1B >VRTX

6. mai 2024, 20:01 UTC

Tulu

Vertex Pharmaceuticals 1Q Adj EPS $4.76 >VRTX

6. mai 2024, 20:01 UTC

Tulu

Vertex Pharmaceuticals 1Q EPS $4.21 >VRTX

23. apr 2024, 18:54 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk

11. apr 2024, 20:18 UTC

Omandamised, ülevõtmised, äriostud

Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It -- IBD

11. apr 2024, 16:54 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Alpine Deal Seen Giving Vertex New Expertise -- Market Talk

11. apr 2024, 14:46 UTC

Omandamised, ülevõtmised, äriostud

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

11. apr 2024, 13:47 UTC

Kuumad aktsiad

Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands -- WSJ

10. apr 2024, 21:47 UTC

Omandamised, ülevõtmised, äriostud

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update

10. apr 2024, 21:09 UTC

Omandamised, ülevõtmised, äriostud

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B -- Update

10. apr 2024, 20:46 UTC

Omandamised, ülevõtmised, äriostud

Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal -- IBD

10. apr 2024, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B

10. apr 2024, 20:04 UTC

Omandamised, ülevõtmised, äriostud

Alpine Immune Sciences: Vertex Will Acquire Alpine for $65 Per Shr or Approximately $4.9B in Cash, Transaction Approved by Both Boards of Directors, Anticipated to Close in 2Q >ALPN

10. apr 2024, 20:03 UTC

Omandamised, ülevõtmised, äriostud

Vertex Subsidiary Will Commence Cash Tender Offer to Purchase All Alpine Common Stk >VRTX

Võrdlus sarnastega

Hinnamuutus

Vertex Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

9.17% tõus

12 kuu keskmine prognoos

Keskmine 510.9 USD 9.17%

Kõrge 600 USD

Madal 325 USD

Põhineb 23 Wall Streeti analüütiku instrumendi Vertex Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

23 ratings

Osta

Hoia

Müü

Põhineb 23 analüütiku instrumendi Vertex Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

463.41 / 481.19Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

94 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.